Loading...
•
Jun 30, 2022
MindMed Q2 2022 Earnings Report
Reported financial results for the quarter ended June 30, 2022, and provided business highlights.
Key Takeaways
MindMed reported its Q2 2022 financial results, highlighting the advancement of its development programs, particularly the Phase 2b dose-optimization trial of MM-120 for generalized anxiety disorder. The company also announced positive safety and tolerability results for its MM-110 program. With a sharpened focus and strengthened leadership team, MindMed is prioritizing its resources towards advancing the MM-120 and MM-402 programs.
Phase 2b dose-optimization trial in patients with General Anxiety Disorder is underway with first patient dosing expected in Q3 2022.
Advanced IND-enabling studies for MM-402 with the Phase 1 investigator-initiated pharmacokinetic/pharmacodynamic trial on track to initiate in Q3 2022.
Drs. Suzanne Bruhn and Roger Crystal were appointed as independent members of the Board of Directors.
Schond L. Greenway was appointed as Chief Financial Officer.
Forward Guidance
MindMed believes its available cash and cash equivalents will be sufficient to meet its operating requirements beyond its key development milestones in 2023 and into 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...